and the French drugmaker is also eyeing testing it in phase 2 and 3 trials in chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic hives, and allergies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback